ArticleNeurology and therapy2026
Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.
Article in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02200770 (A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInebilizumab is used in Japan for relapse prevention in aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). Nationwide post-marketing surveillance (PMS) is underway to evaluate the real-world safety and effectiveness of inebilizumab in Japanese patients with NMOSD.
methodsThis PMS interim analysis assessed safety and effectiveness of inebilizumab in Japanese patients with NMOSD initiating treatment between June 2021 and November 2023, using data through June 2025.
resultsThe safety analysis set included 228 patients, and the effectiveness analysis set included 224 patients after excluding three patients from N-MOmentum (NCT02200770) and one without confirmed anti-AQP4 antibody positivity. Twenty-one (safety analysis set) and 20 (effectiveness analysis set) patients discontinued treatment. In the safety analysis set, 194 patients (85.1%) were female, and the mean ± standard deviation (SD) age was 54.2 ± 13.1 years. Adverse drug reactions (ADRs) occurred in 74 patients (32.5%); 31 (13.6%) were serious. Common ADRs were infections (14.5%, n = 33); serious infections (5.7%, n = 13) included COVID-19 (1.3%, n = 3), COVID-19 pneumonia (0.9%, n = 2), and urinary tract infection (0.9%, n = 2). Two fatal ADRs (interstitial lung disease, sudden cardiac death) occurred, for which a causal relationship with inebilizumab could not be excluded. In the effectiveness analysis set, the annualized relapse rate (95% CI) decreased from 0.40 (0.33-0.47) per person-year during the 2 years before inebilizumab initiation to 0.10 (0.07-0.14) per person-year after inebilizumab initiation. From baseline to 1 year, the proportion of patients receiving neither concomitant oral glucocorticoids nor immunosuppressants increased from 5.4% to 33.0%, and the mean ± SD oral glucocorticoid dose decreased from 11.7 ± 7.9 mg/day to 4.3 ± 4.7 mg/day.
conclusionIn this interim analysis, the safety profile of inebilizumab was consistent with prior evidence and no new safety concerns were identified. Inebilizumab reduced relapse rates and decreased concomitant use of oral glucocorticoids and immunosuppressants in patients with NMOSD. UMIN CLINICAL TRIALS REGISTRY: UMIN000044431.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.